Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 23, 2009

View Archived Issues

Snapshots of studies of CXA-101 presented at ICAAC: I

Anti-sclerostin antibody given with zoledronic acid efficacious in osteoporosis models

Fully human anti-DKK1 monoclonal antibody increases bone formation in osteopenia models

Synthetic pleuromutilin derivatives evaluated by Nabriva for the treatment of bacterial infections

LEAD Therapeutics discloses PARP inhibitors for cancer and other conditions

Allergan describes alpha2B-adrenoceptor agonists for pain and other conditions

Novel estrogen receptor beta agonists reported by Wyeth for the treatment of RA

Quidel cleared to add 2009 H1N1 influenza A virus reactivity to QuickVue package insert

Enzo Life Sciences introduces novel live-cell imaging kit for nuclear components

PF-04287881 shows potent in vitro and in vivo antibacterial activity in respiratory tract infections

S1P1 receptor agonists for the treatment of MS identified by GSK

AEterna Zentaris completes phase I oral AEZS-112 study in cancer

Stallergenes reports results of phase IIb/III trial of recombinant allergen of birch pollen

Enzo Biochem and NIH collaborate on autoimmune uveitis treatment

Maxygen confirms completion of joint venture with Astellas

Provectus completes treatment in phase II PV-10 trial for metastatic melanoma

Dor BioPharma receives NIH grant to develop thermostable vaccines

Cytokinetics presents progress and expansion of development programs

AMDL stockholders approve name change to Radient Pharmaceuticals

FDA grants priority review for Velcade-based therapy in multiple myeloma

AGI Therapeutics completes data analysis of phase III Rezular studies

King Pharmaceuticals launches Embeda for moderate to severe pain

Interim data from phase II trial of 5% Human Albumin Grifols in AD disclosed

Vitae initiates phase I renin inhibitor trial

Prolor Biotech commences phase I clinical trial for its long-acting growth hormone

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...